Lower-dose radiation for HPV-positive throat cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HPV-positive oropharyngeal throat cancer, usually shown by a p16 test
- Your cancer stage is I, II, or III (and it must not have spread to distant sites)
- You are at least 18 years old and can sign consent
- You had a PET/CT scan within the last 6 weeks
- You had a recent checkup within 6 weeks, including weight and weight-loss assessment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
This trial tests whether giving lower doses of radiation to certain parts of the throat can be just as effective as standard doses, while reducing side effects. It is for people with HPV-positive throat cancer, which tends to respond well to treatment.
This trial tests a lower dose of radiation to certain neck areas for people with HPV-related oropharyngeal cancer. The goal is to see if reducing radiation can cause fewer side effects while still curing the cancer.
This Phase 2 trial tests whether people with HPV-positive oropharyngeal (throat) cancer who look “lower risk” can safely receive less intensive treatment. It uses HPV blood test results and cancer staging scans to guide whether treatment can be de-escalated.
This trial tests whether a special PET scan (FMISO PET) can help safely lower the radiation dose for patients with HPV-positive throat cancer. The goal is to reduce side effects while still effectively treating the cancer.
This study tests a new combination of drugs and a vaccine before standard radiation for HPV-positive throat cancer. It aims to use a less intense radiation dose, which may reduce side effects while still being effective.
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.